Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...
- Interim analysis of the EMPRISE real-world evidence study showed that empagliflozin was associated with a reduced risk in all-cause mortality, hospitalization for heart failure and acute kidney ...
Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes may cause joint pain so intense it is disabling, the US Food and Drug Administration (FDA) warned today. Fortunately, the pain goes away, ...
As if last week's Jardiance news wasn't enough to worry makers of DPP-4 diabetes drugs, the FDA has now issued a warning that the class of meds might cause "severe and disabling" joint pain. The ...
Boehringer Ingelheim and Lilly announced preliminary data from the EMPRISE ( EMPagliflozin compaRative effectIveness and SafEty) real-world study at the Academy of Managed Care Pharmacy (AMCP) Annual ...
In a recent large-scale retrospective cohort study published in the journal Primary Care Diabetes, researchers used a comprehensive (n = 10,465) database-derived dataset to evaluate the adherence and ...
The observational study will use information from 3 databases to compare the SGLT2 inhibitor to a competing class of therapy for type 2 diabetes. Early cardiovascular and safety data were presented ...
Sommige resultaten zijn verborgen omdat ze mogelijk niet toegankelijk zijn voor u.
Niet-toegankelijke resultaten weergeven
Feedback